MAPK

MAPキナーゼ

PrepTutorEJDIC

1. Massachusetts / mental age

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/03/14 09:21:00」(JST)

wiki ja

[Wiki ja表示]

MAPK経路。

分裂促進因子活性化タンパク質キナーゼ（ぶんれつそくしんいんしかっせいかタンパクしつキナーゼ、英: Mitogen-activated Protein Kinase、MAPK、EC 2.7.11.24）とはセリン/スレオニンキナーゼの一つであり、何らかの刺激（酸化ストレス、サイトカインなど）を受けて活性化される。全身の細胞に広く発現しており、様々な細胞の機能発現において重要な働きをしている。単にMAP（マップ）キナーゼと略して呼ばれることが多い。

細胞外からの刺激が入ると低分子量Gタンパク質であるRasが活性化され、さらにその下流に続くシグナルカスケードの活性化が引き起こされる。また、MAPKホスファターゼ（MAPK Phosphatase: MKP）による脱リン酸化がMAPKを不活性化し、この機構に対して抑制的に働いている。

狭義には細胞外シグナル調節キナーゼ（英: Extracellular Signal-regulated Kinase、ERK）1/2のみを指すが、広義にはこれに加えてc-Jun N末端キナーゼ（英: c-jun N-terminal kinase、JNK）、p38 MAPK、ERK5およびERK7等の分子をも含み、MAPKファミリーとも呼ばれる。

細胞内シグナル伝達。MAPKカスケードは図中央部。

ERK1/2（古典的MAPK）

ERK1/2はMAPKファミリーの中でも最初に同定されたものであり、古典的MAPKとも称される。ERK1/2は分子量が44kDaのERK1と42kDaのERK2から成り、これらのタンパク質のアミノ酸配列は互いに85%の相同性がある。

ERK1/2の活性化は以下のような機序で生じる。上皮増殖因子受容体（英: Epidermal Growth Factor Receptor、EGFR）等のチロシンキナーゼ関連型受容体にリガンドが結合すると受容体細胞内ドメインのリン酸化が生じる。Grb2等のSH2ドメインを含むアダプタータンパク質が受容体のリン酸化チロシンに結合すると、Grb2はSH3ドメインを介してSosと結合し、Sosを活性化させる。活性化したSosはRasのGDP-GTP交換反応によりRasを活性化させる。以下、RasはMAPキナーゼカスケードへとシグナルを伝えていくが、RasはMAPキナーゼキナーゼキナーゼ (MAPKKK) であるRafを、RafはMAPキナーゼキナーゼであるMAPK/ERK kinase (MEK) を活性化し、このMEKによりERKの活性化が引き起こされる。ERKの活性化にはThr183及びTyr185が重要な働きをしている。通常ERK1/2は細胞質に優位に存在するが、活性化されることにより核内へ移行して転写因子と相互作用することにより転写の制御を行っている。この経路はPD98059、U0126等の試薬によって阻害される。

新規MAPK

JNK

JNKはc-JunのSer63とSer73をリン酸化する活性を持つキナーゼとして同定された。JNKは放射線やリポ多糖 (LPS)、IL-1、浸透圧及び熱ショックなどのストレスにより活性化し、ストレス応答性MAPK (Stress-activated Protein Kinase、SAPK) とも呼ばれる。

JNK遺伝子にはJNK1-3が存在する。JNK1,2は全身の細胞に広く分布しているが、JNK3は主に神経系及び精巣において見られる。

JNK1はアポトーシスや神経変性、細胞の分化・増殖、炎症性サイトカインの産生などの過程に関与している 。JNKは様々な細胞内タンパク質のリン酸化を行い、それらの機能修飾をしている。SP600125によって阻害される。

p38 MAPK

詳細は「p38分裂促進因子活性化タンパク質キナーゼ」を参照

p38MAPKはサイトカインによる刺激や紫外線照射、熱・浸透圧ストレスなどによって活性化されるプロテインキナーゼであり、Thr180/Tyr182のリン酸化がp38MAPKの活性化において重要な働きをしている。p38MAPKの遺伝子にはp38MAPKα,β,γ及びδの4種類が知られている。p38MAPKの上流にはMKK3やMKK6が存在する。SB203580により阻害される。

脚注

出典

• Bruce Alberts 著 "細胞の分子生物学 第4版" Garland Pub. 2004年 ISBN 4315517305

外部リンク

• MAPKシグナルパスウェイ - CSTジャパン
• 分裂促進因子活性化タンパク質キナーゼ - 脳科学辞典

wiki en

[Wiki en表示]

See also: extracellular signal-regulated kinases

Mitogen-activated protein kinase
Identifiers
EC number	2.7.11.24
CAS number	142243-02-5
Databases
IntEnz	IntEnz view
BRENDA	BRENDA entry
ExPASy	NiceZyme view
KEGG	KEGG entry
MetaCyc	metabolic pathway
PRIAM	profile
PDB structures	RCSB PDB PDBe PDBsum
Gene Ontology	AmiGO / EGO
Search PMC articles PubMed articles NCBI proteins

A mitogen-activated protein kinase (MAPK or MAP kinase) is a type of protein kinase that is specific to the amino acids serine, threonine, and tyrosine (i.e., a serine/threonine-specific protein kinase). MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and proinflammatory cytokines. They regulate cell functions including proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis.

MAP kinases are found in eukaryotes only, but they are fairly diverse and encountered in all animals, fungi and plants, and even in an array of unicellular eukaryotes.

MAPKs belong to the CMGC (CDK/MAPK/GSK3/CLK) kinase group. The closest relatives of MAPKs are the cyclin-dependent kinases (CDKs).

Discovery

The first mitogen-activated protein kinase to be discovered was ERK1 (MAPK3) in mammals. Since ERK1 and its close relative ERK2 (MAPK1) are both involved in growth factor signaling, the family was termed "mitogen-activated". With the discovery of other members, even from distant organisms (e.g. plants), it has become increasingly clear that the name is a misnomer, since most MAPKs are actually involved in the response to potentially harmful, abiotic stress stimuli (hyperosmosis, oxidative stress, DNA damage, low osmolarity, infection, etc.). Because plants cannot "flee" from stress, terrestrial plants have the highest number of MAPK genes per organism ever found. Thus the role of mammalian ERK1/2 kinases as regulators of cell proliferation is not a generic, but a highly specialized function.

Types

Most MAPKs have a number of shared characteristics, such as the activation dependent on two phosphorylation events, a three-tiered pathway architecture and similar substrate recognition sites. These are the "classical" MAP kinases. But there are also some ancient outliers from the group as sketched above, that do not have dual phosphorylation sites, only form two-tiered pathways, and lack the features required by other MAPKs for substrate binding. These are usually referred to as "atypical" MAPKs. It is yet unclear if the atypical MAPKs form a single group as opposed to the classical ones.

Activation

X-ray structure of the ERK2 MAP kinase in its active form. Phosphorylated residues are displayed in red. Rendering based on pdb entry 2ERK.

Mitogen-activated protein kinases are catalytically inactive in their base form. In order to become active, they require (potentially multiple) phosphorylation events in their activation loops. This is conducted by specialized enzymes of the STE protein kinase group.

In the case of classical MAP kinases, the activation loop contains a characteristic TxY (threonine-x-tyrosine) motif (TEY in mammalian ERK1 and ERK2, TDY in ERK5, TPY in JNKs, TGY in p38 kinases) that needs to be phosphorylated on both the threonine and the tyrosine residues in order to lock the kinase domain in a catalytically competent conformation. In vivo and in vitro, phosphorylation of tyrosine precedes phosphorylation of threonine, although phosphorylation of either residue can occur in the absence of the other.

This tandem activation loop phosphorylation (that was proposed to be either distributive or processive, dependent on cellular environment) is performed by members of the Ste7 protein kinase family, also known as MAP2 kinases. MAP2 kinases in turn, are also activated by phosphorylation, by a number of different upstream serine-threonine kinases (MAP3 kinases). Because MAP2 kinases display very little activity on substrates other than their cognate MAPK, classical MAPK pathways form multi-tiered, but relatively linear pathways. These pathways can effectively convey stimuli from the cell membrane (where many MAP3Ks are activated) to the nucleus (where only MAPKs may enter) or to many other subcellular targets.

In comparison to the three-tiered classical MAPK pathways, some atypical MAP kinases appear to have a more ancient, two-tiered system. ERK3 (MAPK6) and ERK4 (MAPK4) were recently shown to be directly phosphorylated and thus activated by PAK kinases (related to other MAP3 kinases). In contrast to the classical MAP kinases, these atypical MAPKs require only a single residue in their activation loops to be phosphorylated. The details of NLK and ERK7 (MAPK15) activation remain unknown.

Inactivation of MAPKs is performed by a number of phosphatases. A very conserved family of dedicated phosphatases is the so-called MAP kinase phosphatases (MKPs), a subgroup of dual-specificity phosphatases (DUSPs). As their name implies, these enzymes are capable of hydrolyzing the phosphate from both phosphotyrosine and the phosphothreonine residues. Since removal of either phosphate groups will greatly reduce MAPK activity, essentially abolishing signaling, some tyrosine phosphatases are also involved in inactivating MAP kinases (e.g. the phosphatases HePTP, STEP and PTPRR in mammals).

Signaling cascades

Example for the inner workings of a MAP3 kinase: the activation cycle of mammalian Raf proteins (greatly simplified overview).

As mentioned above, MAPKs typically form multi-tiered pathways, receiving input several levels above the actual MAP kinase. In contrast to the relatively simple, phosphorylation-dependent activation mechanism of MAPKs and MAP2Ks, MAP3Ks have stunningly complex regulation. Many of the better-known MAP3Ks, such as c-Raf, MEKK4 or MLK3 require multiple steps for their activation. These are typically allosterically-controlled enzymes, tighly locked into an inactive state by multiple mechanisms. The first step en route to their activation consist of relieving their autoinhibition by a smaller ligand (such as Ras for c-Raf, GADD45 for MEKK4 or Cdc42 for MLK3). This commonly (but not always) happens at the cell membrane, where most of their activators are bound (note that small G-proteins are constitutively membrane-associated due to prenylation). That step is followed by side-to-side homo- and heterodimerisation of their now accessible kinase domains. Recently determined complex structures reveal that the dimers are formed in an orientation that leaves both their substrate-binding regions free. Importantly, this dimerisation event also forces the MAP3 kinase domains to adopt a partially active conformation. Full activity is only achieved once these dimers transphosphorylate each other on their activation loops. The latter step can also be achieved or aided by auxiliary protein kinases (MAP4 kinases, members of the Ste20 family). Once a MAP3 kinase is fully active, it may phosphorylate its substrate MAP2 kinases, which in turn will phosphorylate their MAP kinase substrates.

In animals

A simplified overview of MAPK pathways in mammals, organised into three main signaling modules (ERK1/2, JNK/p38 and ERK5).

The ERK1/2 pathway of mammals is probably the best-characterized MAPK system. The most important upstream activators of this pathway are the Raf proteins (A-Raf, B-Raf or c-Raf), the key mediators of response to growth factors (EGF, FGF, PDGF, etc.); but other MAP3Ks such as c-Mos and Tpl2/Cot can also play the same role. All these enzymes phosphorylate and thus activate the MKK1 and/or MKK2 kinases, that are highly specific activators for ERK1 and ERK2. The latter phosphorylate a number of substrates important for cell proliferation, cell cycle progression, cell division and differentiation (RSK kinases, Elk-1 transcription factor, etc.)

In contrast to the relatively well-insulated ERK1/2 pathway, mammalian p38 and JNK kinases have most of their activators shared at the MAP3K level (MEKK1, MEKK4, ASK1, TAK1, MLK3, TAOK1, etc.). In addition, some MAP2K enzymes may activate both p38 and JNK (MKK4), while others are more specific for either JNK (MKK7) or p38 (MKK3 and MKK6). Due to these interlocks, there are very few if any stimuli that can elicit JNK activation without simultaneously activating p38 or reversed. Both JNK and p38 signaling pathways are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in adaptation to stress, apoptosis or cell differentiation. JNKs have a number of dedicated substrates that only they can phosphorylate (c-Jun, NFAT4, etc.), while p38s also have some unique targets (e.g. the MAPKAP kinases MK2 and MK3), ensuring the need for both in order to respond to stressful stimuli.

ERK5 is part of a fairly well-separated pathway in mammals. Its sole specific upstream activator MKK5 is turned on in response to the MAP3 kinases MEKK2 and MEKK3. The specificity of these interactions are provided by the unique architecture of MKK5 and MEKK2/3, both containing N-terminal PB1 domains, enabling direct heterodimerisation with each other. The PB1 domain of MKK5 also contributes to the ERK5-MKK5 interaction: it provides a special interface (in addition to the D-motif found in MKK5) through which MKK5 can specifically recognize its substrate ERK5. Although the molecular-level details are poorly known, MEKK2 and MEKK3 respond to certain developmental cues to direct endothel formation and cardiac morphogenesis. While also implicated in brain development, the embryonic lethality of ERK5 inactivation due to cardiac abnormalities underlines its central role in mammalian vasculogenesis. It is notable, that conditional knockout of ERK5 in adult animals is also lethal, due to the widespread disruption of endothelial barriers. Mutations in the upstream components of the ERK5 pathway (the CCM complex) are thought to underlie cerebral cavernous malformations in humans.

In fungi

Overview of MAPK pathways in yeast. Non-canonical components of the five known modules (mating, filamentation, hyperosmosis, cell wall integrity, sporulation pathways) are colored in blue.

MAPK pathways of fungi are also well studied. In yeast, the Fus3 MAPK is responsible for cell cycle arrest and mating in response to pheromone stimulation. The pheromone alpha-factor is sensed by a seven transmembrane receptor. The recruitment and activation of Fus3 pathway components are strictly dependent on heterotrimeric G-protein activation. The mating MAPK pathway consist of three tiers (Ste11-Ste7-Fus3), but the MAP2 and MAP3 kinases are shared with another pathway, the Kss1 or filamentous growth pathway. While Fus3 and Kss1 are closely related ERK-type kinases, yeast cells can still activate them separately, with the help of a scaffold protein Ste5 that is selectively recruited by the G-proteins of the mating pathway. The trick is that Ste5 can associate with and "unlock" Fus3 for Ste7 as a substrate in a tertiary complex, while it does not do the same for Kss1, leaving the filamentous growth pathway to be activated only in the absence of Ste5 recruitment.

Fungi also have a pathway reminiscent of mammalian JNK/p38 signaling. This is the Hog1 pathway: activated by high osmolarity (in S. cerevisiae) or a number of other abiotic stresses (in S. pombe). The MAP2 kinase of this pathway is called Pbs2 (related to mammalian MKK3/4/6/7), the dedicated MAP3 kinases involved in activation are Ssk2 and SSk22. The system in S. cerevisiae is activated by a sophisticated osmosensing module consisting of the Sho1 and Sln1 proteins, but it is yet unclear how other stimuli can elicit activation of Hog1. Yeast also displays a number of other MAPK pathways without close homologs in animals, such as the cell wall integrity pathway (Mpk1/Slt2) or the sporulation pathway (Smk1).

In plants

Despite the high number of MAPK genes, MAPK pathways of higher plants were studied less than animal or fungal ones. Although their signaling appears very complex, the MPK3, MPK4 and MPK6 kinases of Arabidopsis thaliana are key mediators of responses to osmotic shock, oxidative stress, response to cold and involved in anti-pathogen responses. In addition, they are also involved in morphogenesis, since MPK4 mutants display severe dwarfism.

Evolutionary relationships

The evolutionary origins of human mitogen-activated protein kinases (MAPKs)

Members of the MAPK family can be found in every eukaryotic organism examined so far. In particular, both classical and atypical MAP kinases can be traced back to the root of the radiation of major eukaryotic groups. Terrestrial plants contain four groups of classical MAPKs (MAPK-A, MAPK-B, MAPK-C and MAPK-D) that are involved in response to myriads of abiotic stresses. However, none of these groups can be directly equated to the clusters of classical MAPKs found in opisthokonts (fungi and animals). In the latter, the major subgroups of classical MAPKs form the ERK/Fus3-like branch (that is further sub-divided in metazoans into ERK1/2 and ERK5 subgroups), and the p38/Hog1-like kinases (that has also split into the p38 and the JNK subgroups in multicellular animals). In addition, there are several MAPKs in both fungi and animals, whose origins are less clear, either due to high divergence (e.g. NLK), or due to possibly being an early offshoot to the entire MAPK family (ERK3, ERK4, ERK7). In vertebrates, due to the twin whole genome duplications after the cephalochordate/vertebrate split, there are several paralogs in every group. Thus ERK1 and ERK2 both correspond to the Drosophila kinase rolled, JNK1, JNK2 and JNK3 are all orthologous to the gene basket in Drosophila. Although among the p38 group, p38 alpha and beta are clearly paralogous pairs, and so are p38 gamma and delta in vertebrates, the timing of the base split is less clear, given that many metazoans already possess multiple p38 homologs (there are three p38-type kinases in Drosophila, Mpk2(p38a), p38b and p38c). The single ERK5 protein appears to fill a very specialized role (essential for vascular development in vertebrates) wherever it is present. This lineage has been deleted in protostomes, together with its upstream pathway components (MEKK2/3, MKK5), although they are clearly present in cnidarians, sponges and even in certain unicellular organisms (e.g. the choanoflagellate Monosiga brevicollis) closely related to the origins of multicellular animals.

The split between classical and some atypical MAP kinases happened quite early. This is suggested not just by the high divergence between extant genes, but also recent discoveries of atypical MAPKs in primitive, basal eukaryotes. The genome sequencing of Giardia lamblia revealed the presence of two MAPK genes, one of them similar to the already-well-known mammalian MAPKs (ERKs, p38s, etc.), the other one showing similarities to the mammalian ERK7 protein. The situation is similar in the multicellular amoeba Dictyostelium discoideum, where the ddERK1 protein appears to be a classical MAPK, while ddERK2 more closely resembles our ERK7 and ERK3/4 proteins. Atypical MAPKs can also be found in higher plants, although they are poorly known. Similar to the situation in mammals, most aspects of atypical MAPKs are uncharacterized due to the lack of research focus on this area.

Substrate and partner recognition

The overview of the D-motif dependent MAPK interactions and substrate recognition. All cited examples refer to the interactions of the mammalian ERK2 protein.

As typical for the CMGC kinase group, the catalytic site of MAP kinases has a very loose consensus sequence for substrates. Like all their relatives, they only require the target serine / threonine amino acids to be followed by a small amino acid, preferably proline ("proline-directed kinases"). But as SP/TP sites are extremely common in all proteins, additional substrate-recognition mechanisms have evolved to ensure signaling fidelty. Unlike their closest relatives, the cyclin-dependent kinases (CDKs), where substrates are recognized by the cyclin subunit, MAPKs associate with their substrates via auxiliary binding regions on their kinase domains. The most important such region consists of the hydrophobic docking groove and the negatively charged CD-region. Together they recognize the so-called MAPK docking or D-motifs (also called kinase interaction motif / KIM). D-motifs essentially consist of one or two positively charged amino acids, followed by alternating hydrophobic residues (mostly leucines), typically upstream of the phosphorylation site by 10-50 amino acids. Many of the known MAPK substrates contain such D-motifs that can not only bind to, but also provide specific recognition by certain MAPKs. Interestingly, D-motifs are not restricted to substrates: MAP2 kinases also contain such motifs on their N-termini that are absolutely required for MAP2K-MAPK interaction and MAPK activation. Similarly, both dual-specificity MAP kinase phosphatases and MAP-specific tyrosine phosphatases bind to MAP kinases through the same docking site. D-motifs can even be found in certain MAPK pathway regulators and scaffolds (e.g. in the mammalian JIP proteins).

Other, less well characterised substrate-binding sites also exist. One such site (the DEF site) is formed by the activation loop (when in the active conformation) and the MAP kinase-specific insert below it. This site can accommodate peptides with an FxFP consensus sequence, typically downstream of the phosphorylation site. Note that the latter site can only be found in proteins that need to selectively recognize the active MAP kinases, thus they are almost exclusively found in substrates. Different motifs may cooperate with each other, as in the Elk family of transcription factors, that possess both a D-motif and an FxFP motif. The presence of an FxFP motif in the KSR1 scaffold protein also serves to make it an ERK1/2 substrate, providing a negative feedback mechanism to set the correct strength of ERK1/2 activation.

Scaffold proteins

Since the discovery of Ste5 in yeast, scientists were on the hunt to discover similar non-enzymatic scaffolding pathway elements in mammals. There are indeed a number of proteins involved in ERK signaling, that can bind to multiple elements of the pathway: MP1 binds both MKK1/2 and ERK1/2, KSR1 and KSR2 can bind B-Raf or c-Raf, MKK1/2 and ERK1/2. Analogous proteins were also discovered for the JNK pathway: the JIP1/JIP2 and the JIP3/JIP4 families of proteins were all shown to bind MLKs, MKK7 and any JNK kinase. Unfortunately, unlike the yeast Ste5, the mechanisms by which they regulate MAPK activation are considerably less understood. While Ste5 actually forms a ternary complex with Ste7 and Fus3 to promote phosphorylation of the latter, known mammalian scaffold proteins appear to work by very different mechanisms. For example, KSR1 and KSR2 are actually MAP3 kinases and related to the Raf proteins. Although KSRs alone display negligible MAP3 kinase activity, KSR proteins can still participate in the activation of Raf kinases by forming side-to-side heterodimers with them, providing an allosteric pair to turn on each enzymes. JIPs on the other hand, are apparently transport proteins, responsible for enrichment of MAPK signaling components in certain compartments of polarized cells. In this context, JNK-dependent phosphorylation of JIP1 (and possibly JIP2) provides a signal for JIPs to release the JIP-bound and inactive upstream pathway components, thus driving a strong local positive feedback loop. This sophisticated mechanism couples kinesin-dependent transport to local JNK activation, not only in mammals, but also in the fruitfly Drosophila melanogaster.

As therapeutic targets

Since the ERK signaling pathway is involved in both physiological and pathological cell proliferation, it is natural that ERK1/2 inhibitors would represent a desirable class of antineoplastic agents. Indeed, many of the proto-oncogenic "driver" mutations are tied to ERK1/2 signaling, such as constitutively active (mutant) receptor tyrosine kinases, Ras or Raf proteins. Although no MKK1/2 or ERK1/2 inhibitors were developed for clinical use, kinase inhibitors that also inhibit Raf kinases (e.g. Sorafenib) are successful antineoplastic agents against various types of cancer.

JNK kinases are implicated in the development of insulin resistance in obese individuals as well as neurotransmitter excitotoxicity after ischaemic conditions. Inhibition of JNK1 ameliorates insulin resistance in certain animal models. Mice that were genetically engineered to lack a functional JNK3 gene - the major isoform in brain - display enhanced ischemic tolerance and stroke recovery. Although small-molecule JNK inhibitors are under development, none of them proved to be effective in human tests yet. Interestingly, a peptide-based JNK inhibitor (AM-111, a retro-inverse D-motif peptide from JIP1, formerly known as XG-102) is also under clinical development for sensorineural hearing loss.

p38 was once believed to be a perfect target for anti-inflammatory drugs. Yet the failure of more than a dozen chemically different compounds in the clinical phase suggests that p38 kinases might be poor therapeutic targets in autoimmune diseases. Many of these compounds were found to be hepatotoxic to various degree and tolerance to the anti-inflammatory effect developed within weeks.

See also

• Signal transduction
• MAP kinase kinase
• MAP kinase kinase kinase
• MAP kinase kinase kinase kinase
• MAPK1 (ERK2)
• MAPK3 (ERK1)
• MAPK7 (ERK5)
• MAPK8 (JNK1)
• MAPK9 (JNK2)
• MAPK10 (JNK3)
• MAPK11 (p38-beta)
• MAPK12 (p38-gamma)
• MAPK13 (p38-delta)
• MAPK14 (p38-alpha)
• MAPK4 (ERK4: atypical MAPK)
• MAPK6 (ERK3: atypical MAPK)
• MAPK15 (ERK7/ERK8: atypical MAPK)
• NLK (Nemo-like kinase: atypical MAPK)
• ERK1/2 kinases
• ERK1/2 pathway
• JNK kinases
• p38 MAP kinases

References

External links

• MAP Kinase Resource .
• Table of names for mitogen-activated kinases.
• MAPK cascade picture
• Mitogen-Activated Protein Kinases at the US National Library of Medicine Medical Subject Headings (MeSH)
• Model of MAPK ultrasensitivity in BioModels Database
• Drosophila rolled - The Interactive Fly

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 転移性黒色腫（メラノーマ）の分子標的療法molecularly targeted therapy for metastatic melanoma [show details]
  …had acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, then received immune checkpoint inhibitors, and are at least 12 weeks from their last MAPK-targeted therapy. In a prospective …
• 2. 進行皮膚黒色腫に対するマネージメントの概要overview of the management of advanced cutaneous melanoma [show details]
  …melanoma include surgical metastasectomy, immunotherapy, targeted inhibition of the mitogen-activated protein kinase (MAPK) pathway, and radiation therapy to symptomatic sites of metastases Although cytotoxic …
• 3. タモキシフェンによるホルモン療法を受ける女性の不正子宮出血と子宮の病理abnormal uterine bleeding and uterine pathology in women on tamoxifen therapy [show details]
  …stimulate endometrial proliferation. Tamoxifen appears to promote (1) cell proliferation through MAP kinase pathways, c-MYC, and insulin-like growth factor 1 (IGF1) pathways, (2) cell proliferation and invasion…
• 4. 黒色腫（メラノーマ）の分子生物学the molecular biology of melanoma [show details]
  …between MITF and the mitogen-activated protein kinase (MAPK) pathway, which is relevant to therapies targeting BRAF. MITF serves as a direct substrate for phosphorylation at serine 73 by MAPK . One of the critical …
• 5. ヌーナン症候群noonan syndrome [show details]
  …germline mutations in genes encoding proteins that interact within the Ras-mitogen-activated protein kinase (Ras-MAPK) pathway Ras-MAPK pathway signaling is crucial to many cellular functions, including proliferation …

English Journal

• PMID 25797415

• Flt3 ligand induces monocyte proliferation and enhances the function of monocyte-derived dendritic cells in vitro.

• Kim SW1, Choi SM, Choo YS, Kim IK, Song BW, Kim HS.
• Journal of cellular physiology.J Cell Physiol.2015 Aug;230(8):1740-9. doi: 10.1002/jcp.24824.
• Flt3 ligand (FL), a potent hematopoietic cytokine, plays an important role in development and activation of dendritic cells (DCs) and natural killer cells (NK). Although some post-receptor signaling events of FL have been characterized, the role of FL on Flt3 expressing human peripheral blood monocy
• PMID 25215878

• Cordyceps sinensis polysaccharide inhibits PDGF-BB-induced inflammation and ROS production in human mesangial cells.

• Wang Y1, Wang Y2, Liu D2, Wang W2, Zhao H2, Wang M2, Yin H3.
• Carbohydrate polymers.Carbohydr Polym.2015 Jul 10;125:135-45. doi: 10.1016/j.carbpol.2015.02.012. Epub 2015 Feb 19.
• CPS-F, a polysaccharide derived from Cordyceps sinensis, is a potential anti-inflammatory and anti-oxidative agent. We demonstrated that CPS-F not only inhibits platelet-derived growth factor BB (PDGF-BB)-induced intracellular reactive oxygen species (ROS) generation, and up-regulation of tumor necr
• PMID 25857968

Japanese Journal

• The Regulation of the Expression of ABCG2 Gene through Mitogen-Activated Protein Kinase Pathways in Canine Lymphoid Tumor Cell Lines

• TOMIYASU Hirotaka,GOTO-KOSHINO Yuko,FUJINO Yasuhito,OHNO Koichi,TSUJIMOTO Hajime
• Journal of Veterinary Medical Science, 2014
• … Treatment with phorbol 12-myristate 13-acetate (PMA), the protein kinase C (PKC) activator, stimulated MAPK/ERK pathway in GL-1, UL-1 and Ema cells and JNK pathway in UL-1 and Ema cells. … When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells. …
• NAID 130003382366

• Sigma-1 Receptor Antagonist, BD1047 Reduces Nociceptive Responses and Phosphorylation of p38 MAPK in Mice Orofacial Formalin Model

• Roh Dae-Hyun,Yoon Seo-Yeon
• Biological and Pharmaceutical Bulletin, 2014
• … 38) mitogen-activated protein kinases (MAPK), which are closely linked to pain signaling and sensitization, in TNC was modified by BD1047. …
• NAID 130003382117

• Nobiletin Suppresses MMP-9 Expression through Modulation of p38 MAPK Activity in Human Dermal Fibrobalsts

• Kim Jin-Ju,Korm Sovannarith,Kim Won-Seok,Kim Ok-Seon,Lee Ji-Seon,Min Hyung-Geun,Chin Young-Won,Cha Hyuk-Jin
• Biological and Pharmaceutical Bulletin 37(1), 158-163, 2014
• … Sustained p38 mitogen activated protein kinase (MAPK) activity, closely associated with induction of MMP-9 under stress condition, was markedly reduced by NB treatment, which implies that modulation of p38MAPK by nobiletin is responsible for reduction of MMP9 expression. …
• NAID 130003382097

Related Links

• MAPK経路とは - WWW3 関西医大学術サーバ

MAPK経路とは MAP kinase（mitogen-activated protein kinase、以下MAPK）は、酵母から植物・高等動物に至るまで広く真核生物に保存されたセリン／スレオニンキナーゼであり、活性化にともなって核内へと移行することから、細胞外の ...

• CSTジャパン - MAPK カスケード (Mitogen-Activated Protein ...

米国CST社の日本法人CSTジャパン株式会社【公式サイト】MAPK カスケード (Mitogen-Activated Protein Kinase Cascades)ページ。高品質の研究用試薬、米国本社の開発研究者による技術的サポートをご提供しております。

• MAPK シグナル伝達 | アブカム

MAPK シグナル伝達経路は、運動、アポトーシスなど、細胞のさまざまな機能に関与しています。 ... カスタム・ソリューション & パートナーシップ あなたの診断法や治療法を発展させるための、カスタム抗体開発およびコマーシャル ...

Related Pictures

---

★リンクテーブル★

リンク元	「ERK」「受容体チロシンキナーゼ」「MAPキナーゼ」「MAPキナーゼスーパーファミリーカスケード」「JNK」
拡張検索	「p38 MAPK」「MAPK-ERK kinase 1」「MAPK-ERKキナーゼ1」「MAPK経路」
関連記事	「MAP」「MA」

「ERK」

　　[★]

同

[[]] extracellular-signal-regulated kinase

関

MAPキナーゼスーパーファミリーカスケード

• MAPKファミリーに含まれるERKファミリーを構成
• キナーゼサブドメインVIIIの活性化ループに存在するリン酸化部位の配列がTEY
• セリンスレオニンキナーゼ
• MAPKKであるMEK1,MEK2によってスレオニンとチロシン残基がリン酸化され、活性化される。
• ERK1/2の基質

• 転写因子：Elk-1, Ets1, Sapla, STAT
• キナーゼ：p90rsk(p90 ribosomal S6 kinase), MNK1/MNK2
• cPLA2
• EGF受容体
• Sos
• 細胞骨格構成タンパク質(Map2, Tau)

• ERK1
• ERK2

同

extracellular-signal-regulated kinase

「受容体チロシンキナーゼ」

　　[★]

英

receptor tyrosine kinase receptor, tyrosine kinase RTK

同？

チロシンキナーゼ受容体

カスケード

• リガンド結合→レセプターの二量体化→レセプターの細胞膜内領域を自己リン酸化

→ホスホリパーゼC→ジアシルグリセロール→PKC→増殖因子の活性化

→Grb2→SOS→Ras→Raf-1(MAPKKK)→MEK(MAPKK)→Erk1/Erk2(MAPK)→(核移行)→ELK1→c-fos

→PI3キナーゼ→PI(3,4,5)P3→PDK1→PKB→増殖因子の活性化

「MAPキナーゼ」

　　[★]

英

MAP kinase, mitogen-activated protein kinase, MAPK

同

マイトジェン活性化プロテインキナーゼ、マップキナーゼ

関

MAPキナーゼスーパーファミリーカスケード。mitogen-activated protein

• リン酸化部位：スレオニン、チロシン
• MAPKKによってスレオニンとチロシン残基がリン酸化される。

MAPKスーパーファミリー

• ERK1/ERK2
• JNK1/JNK2/JNK3
• p38α/p38β/p38γ/p38δ
• ERK5

「MAPキナーゼスーパーファミリーカスケード」

　　[★]

層	増殖因子
細胞膜	Grb2 Sos Ras
細胞質
MAPKKKK	PAK3
MAPKKK	Raf-1/A-Raf
MAPKK	B-Raf/Mos
MAPK	MEK1/MEK2
基質	ERK1/ERK2, p90rsk, MNK1/MNK2, Sos, cPLA2, EGFR, Elk-1, Ets1, Sap1a, STAT, Map2, Tau

「JNK」

　　[★]

同

c-Jun N-terminal kinase, c-Jun NH2-terminal kinase, JNK mitogen-activated protein kinase

SAPK

関

MAPキナーゼスーパーファミリーカスケード

• MAPKファミリーの一つ。JNK1/2/3がある。
• JNK1：全身組織に発現
• JNK2：全身組織に発現
• JNK3：脳に限局

「p38 MAPK」

　　[★]

• p38マイトジェン活性化プロテインキナーゼ

関

mitogen-activated protein kinase p38、p38 MAP kinase、p38 mitogen-activated protein kinase、p38 protein kinase

「MAPK-ERK kinase 1」

　　[★]

• MAPK-ERKキナーゼ1、MAPキナーゼキナーゼ1

関

MAP kinase kinase 1、MEK1

「MAPK-ERKキナーゼ1」

　　[★]

英

MAPK-ERK kinase 1、MEK1

関

MAPキナーゼキナーゼ1

「MAPK経路」

　　[★]

英

MAPK pathway

関

MAPキナーゼ経路

「MAP」

　　[★]

• 僧帽弁輪形成術 mitral annuloplasty
• Miller assessment for Pre-schoolers
• 平均動脈圧 mean arterial pressure
• 平均気道内圧 mean airway pressure
• mannitol adenine phosphate
• リン酸アンモニウムマグネシウム magnesium ammonium phosphate

「MA」

　　[★]

• 僧帽弁閉鎖症 僧帽弁閉鎖 mitral atresia
• 僧帽弁輪 mitral annulus